Article
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2026
Stensland Elin Marie, Stensgaard Simone, Eide Inger Johanne Z, Nilssen Yngvar, Horndalsveen Henrik, Cicenas Saulius, Grønberg Bjørn Henning, Ekman Simon, Hansen Karin Holmskov, Sorensen Boe Sandahl, Brustugun Odd Terje
Abstract excerpt
INTRODUCTION: Osimertinib has documented CNS activity, but there is little data on the effect on untreated brain metastases (BM). We assessed the efficacy of osimertinib in patients with or without active BM and investigated whether circulating tumour DNA (ctDNA) at baseline provides prognostic information. METHODS: In this single-arm phase II clinical trial, patients with EGFR-mutated non-small cell lung cancer...
Topics
Join the communities discussing this publication.